Neos Therapeutics Inc. (NASDAQ:NEOS) shares were down 4.6% during trading on Friday . The company traded as low as $8.75 and last traded at $8.75, with a volume of 67,657 shares changing hands. The stock had previously closed at $9.17.

A number of research analysts have weighed in on NEOS shares. BMO Capital Markets started coverage on Neos Therapeutics in a report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 target price on the stock. Zacks Investment Research downgraded Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Royal Bank Of Canada reduced their target price on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a report on Tuesday, May 17th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Neos Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.75.

The company’s market cap is $142.00 million. The firm has a 50 day moving average of $9.48 and a 200-day moving average of $9.90.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.79) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.08. Analysts forecast that Neos Therapeutics Inc. will post ($4.88) earnings per share for the current fiscal year.

In related news, Director Gregory J. Robitaille purchased 7,442 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The stock was bought at an average price of $7.55 per share, for a total transaction of $56,187.10. Following the completion of the transaction, the director now owns 55,677 shares in the company, valued at approximately $420,361.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Juergen Martens purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The stock was bought at an average price of $9.90 per share, with a total value of $99,000.00. Following the transaction, the insider now owns 10,000 shares of the company’s stock, valued at approximately $99,000. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP increased its stake in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent reporting period.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).